Cure Glomerulonephropathy (CureGN)
The core CureGN study is a multi-center prospective cohort study of approximately 2,400 adult and pediatric patients with biopsy-documented IgAN, FSGS, MN, and MCD. For each disease category, approximately 600 participants will be recruited. Participants will be recruited concurrently from each of the four Participating Clinical Center (PCC) networks: Columbia University, Midwest Pediatric Nephrology Consortium, University of North Carolina, and University of Pennsylvania. Each PCC represents multiple clinical sites, with current representation in the United States, Canada, and Italy. Participants meeting the enrollment criteria below will be enrolled if they or their legally authorized representative(s) provide signed informed consent. Patients will be followed until death, withdrawal from the study, or end of study. For the initial funding period, total study duration is approximately 4 years. Participant recruitment may occur at any point during the study period, and at least until recruitment goals are met for each disease category.
Diabetic Kidney Disease
Katherine Tuttle MD